Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Omacetaxine Mepesuccinate

FDA-approved product (powder, subcutaneous), marketed as Synribo.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Omacetaxine Mepesuccinate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other antineoplastic agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Omacetaxine Mepesuccinate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Omacetaxine Mepesuccinate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML

    NCT07643636 · start 2026-06-30

    Registered record
    Registry ID
    NCT07643636
    Conditions
    AML (Acute Myeloid Leukemia)
    Interventions
    Chidamide (Chi)+VAH
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-06-30
    Completion
    2029-06-01
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAML (Acute Myeloid Leukemia)
    InterventionChidamide (Chi)+VAH
    PhasePhase 2
    Registry statusNot yet recruiting

  • HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).

    NCT07517510 · start 2026-04-01

    Registered record
    Registry ID
    NCT07517510
    Conditions
    Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL)
    Interventions
    HVA
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Enrolling by invitation
    Start
    2026-04-01
    Completion
    2027-12-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNewly Diagnosed Mixed Phenotype Acute Leukemia (MPAL)
    InterventionHVA
    PhasePhase 2
    Registry statusEnrolling by invitation

  • Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy

    NCT07651163 · start 2026-03-01

    Registered record
    Registry ID
    NCT07651163
    Conditions
    Acute Myeloid Leukemia (AML); Lisaftoclax
    Interventions
    Lisaftoclax+daunorubicin+cytarabine; Lisaftoclax+homoharringtonine+cytarabine+aclarubicin; Lisaftoclax+azacitidine; Lisaftoclax+ cytarabine; Lisaftoclax+azacitidine or azacitidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Enrolling by invitation
    Start
    2026-03-01
    Completion
    2029-12
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia (AML); Lisaftoclax
    InterventionLisaftoclax+daunorubicin+cytarabine; Lisaftoclax+homoharringtonine+cytarabine+aclarubicin; Lisaftoclax+azacitidine; Lisaftoclax+ cytarabine +1 more
    PhasePhase 2 / Phase 3
    Registry statusEnrolling by invitation

  • Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy

    NCT07651176 · start 2026-03-01

    Registered record
    Registry ID
    NCT07651176
    Conditions
    Acute Myeloid Leukemia; Lisaftoclax
    Interventions
    Lisaftoclax+daunorubicin+cytarabine; Lisaftoclax+homoharringtonine+cytarabine+aclarubicin; Daunorubicin+cytarabine; Lisaftoclax+cytarabine; Lisaftoclax+azacitidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Enrolling by invitation
    Start
    2026-03-01
    Completion
    2029-12
    Enrolment
    267

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Lisaftoclax
    InterventionLisaftoclax+daunorubicin+cytarabine; Lisaftoclax+homoharringtonine+cytarabine+aclarubicin; Daunorubicin+cytarabine; Lisaftoclax+cytarabine +1 more
    PhasePhase 2 / Phase 3
    Registry statusEnrolling by invitation

  • Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT

    NCT07319793 · start 2026-01-01

    Registered record
    Registry ID
    NCT07319793
    Conditions
    Acute Myeloid Leukemia; Myelodysplastic Syndromes (MDS)
    Interventions
    Prophylactic DLI; Preemptive DLI
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-01-01
    Completion
    2028-06-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Myelodysplastic Syndromes (MDS)
    InterventionProphylactic DLI; Preemptive DLI
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML

    NCT07172204 · start 2025-09-16

    Registered record
    Registry ID
    NCT07172204
    Conditions
    Intensive Chemotherapy Unfit; Newly Diagnosed Acute Myeloid Leukemia (AML); Age ≥60
    Interventions
    Alternately treated with VA/low CHA regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-09-16
    Completion
    2029-07-31
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntensive Chemotherapy Unfit; Newly Diagnosed Acute Myeloid Leukemia (AML); Age ≥60
    InterventionAlternately treated with VA/low CHA regimen
    PhasePhase 2
    Registry statusRecruiting

  • Efficacy and Safety of VAH as a Bridging Regimen to Allo-HCT in Relapsed/Refractory AML

    NCT07091006 · start 2025-08-01

    Registered record
    Registry ID
    NCT07091006
    Conditions
    Relapse Leukemia
    Interventions
    VAH
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-08-01
    Completion
    2028-05-01
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapse Leukemia
    InterventionVAH
    PhasePhase 2
    Registry statusNot yet recruiting

  • Clinical Study on Neoadjuvant Therapy of Homoharringtonine Combined With Androgen Deprivation for Prostate Cancer

    NCT06834321 · start 2025-03-19

    Registered record
    Registry ID
    NCT06834321
    Conditions
    Prostate CA
    Interventions
    Homoharringtonine combined with androgen deprivation therapy; Placebo combined with androgen deprivation treatment group; radical prostatectomy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-03-19
    Completion
    2027-09-28
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate CA
    InterventionHomoharringtonine combined with androgen deprivation therapy; Placebo combined with androgen deprivation treatment group; radical prostatectomy
    PhasePhase 2
    Registry statusRecruiting

  • Newly-diagnosed Pediatric T-cell ALL Protocol

    NCT06855810 · start 2025-03-11

    Registered record
    Registry ID
    NCT06855810
    Conditions
    Acute Lymphoblastic Leukemia; Childhood Leukemia, Acute Lymphoblastic; T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
    Interventions
    Venetoclax; Dasatinib; homoharringtonine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2025-03-11
    Completion
    2031-06
    Enrolment
    610

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia; Childhood Leukemia, Acute Lymphoblastic; T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
    InterventionVenetoclax; Dasatinib; homoharringtonine
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML

    NCT06744556 · start 2025-01-21

    Registered record
    Registry ID
    NCT06744556
    Conditions
    AML
    Interventions
    daunorubicin; Venetoclax; cytarabine; azacitidine; Homoharringtonine; Idarubicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2025-01-21
    Completion
    2028-06-01
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAML
    Interventiondaunorubicin; Venetoclax; cytarabine; azacitidine +2 more
    PhasePhase 2
    Registry statusActive not recruiting

  • CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML

    NCT06470841 · start 2024-09-20

    Registered record
    Registry ID
    NCT06470841
    Conditions
    Acute Myeloid Leukemia
    Interventions
    CHG Combined With Venetoclax and Azacytidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2024-09-20
    Completion
    2028-12
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionCHG Combined With Venetoclax and Azacytidine
    PhasePhase 2
    Registry statusNot yet recruiting

  • Intermediate-dose HAD Regimen for CEBPA Double-mutated AML

    NCT06529250 · start 2024-08-13

    Registered record
    Registry ID
    NCT06529250
    Conditions
    AML
    Interventions
    HAD; Daunorubicin+Cytarabine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-08-13
    Completion
    2029-09-01
    Enrolment
    148

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAML
    InterventionHAD; Daunorubicin+Cytarabine
    PhaseNot applicable
    Registry statusRecruiting

  • MRD-positive AML Clinical Study

    NCT07131059 · start 2024-05-11

    Registered record
    Registry ID
    NCT07131059
    Conditions
    AML, Adult
    Interventions
    Ivosidenib; Gilteritinib; Venetoclax; Avapritinib; Daunorubicin; Cytarabine; Idarubicin; Mitoxantrone; Homoharringtonine; Azacitidine; Ruxolitinib; Trametinib
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-05-11
    Completion
    2028-10-30
    Enrolment
    537

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAML, Adult
    InterventionIvosidenib; Gilteritinib; Venetoclax; Avapritinib +8 more
    PhaseNot applicable
    Registry statusRecruiting

  • Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL

    NCT06361329 · start 2024-04-03

    Registered record
    Registry ID
    NCT06361329
    Conditions
    ETP-ALL
    Interventions
    Homoharringtonine; venetoclax; Cytarabine; G-CSF; Vindesine; Daunorubicin; cyclophosphamide; Dexamethasone; L-ASP
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-04-03
    Completion
    2027-03-31
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionETP-ALL
    InterventionHomoharringtonine; venetoclax; Cytarabine; G-CSF +5 more
    PhasePhase 3
    Registry statusRecruiting

  • Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients

    NCT06394011 · start 2024-02-15

    Registered record
    Registry ID
    NCT06394011
    Conditions
    Intermediate Risk Acute Myeloid Leukemia; High Risk Acute Myeloid Leukemia
    Interventions
    venetoclax, azacitidine and HAAG regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-02-15
    Completion
    2026-12-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntermediate Risk Acute Myeloid Leukemia; High Risk Acute Myeloid Leukemia
    Interventionvenetoclax, azacitidine and HAAG regimen
    PhasePhase 2
    Registry statusRecruiting